Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure
Authors: Mark B. McClellan, Jerod M. Loeb, Carolyn M. Clancy, Gary S. Francis, Alice K. Jacobs, Kenneth W. Kizer, Margaret E. O'Kane, Michael J. Wolk
Journal: Annals of Internal Medicine (2005)

Letters1 March 2005Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart FailureMark B. McClellan, MD, PhD, Jerod M. Loeb, PhD, Carolyn M. Clancy, MD, Gary S. Francis, MD, Alice K. Jacobs, MD, Kenneth W. Kizer, MD, MPH, Margaret E. O'Kane, and Michael J. Wolk, MDMark B. McClellan, MD, PhDFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., Jerod M. Loeb, PhDFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., Carolyn M. Clancy, MDFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., Gary S. Francis, MDFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., Alice K. Jacobs, MDFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., Kenneth W. Kizer, MD, MPHFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., Margaret E. O'KaneFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699., and Michael J. Wolk, MDFrom Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-5-200503010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITORS:As noted in Lee and colleagues' meta-analysis (1), the evidence for use of angiotensin-receptor blockers (ARBs) for chronic heart failure and acute myocardial infarction (MI) with left ventricular systolic dysfunction has evolved, and relevant performance measures now need to be revised. The Centers for Medicare & Medicaid Services (CMS) and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) have been working toward this goal with the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America since the publication of the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial (2) and the ...References1. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141:693-704. [PMID: 15520426] LinkGoogle Scholar2. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906. [PMID: 14610160] CrossrefMedlineGoogle Scholar3. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6. [PMID: 13678870] CrossrefMedlineGoogle Scholar4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:671-719. [PMID: 15358045] MedlineGoogle Scholar5. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996-3007. [PMID: 11739319] MedlineGoogle Scholar6. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-93. [PMID: 14761900] CrossrefMedlineGoogle Scholar7. Executive Council Of The Heart Failure Society Of America. Implications of recent clinical trials for heart failure performance measures. J Card Fail. 2004;10:4-5. [PMID: 14966767] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMeta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction Victor C. Lee , David C. Rhew , Michelle Dylan , Enkhe Badamgarav , Glenn D. Braunstein , and Scott R. Weingarten Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Michael J. Peeters and James P. Tsikouris Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Loren D. Regier and Brent Jensen Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Victor C. Lee , David C. Rhew , and Glenn D. Braunstein Metrics Cited ByACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults With Heart FailureACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults With Heart FailureSection 7: Heart Failure in Patients With Reduced Ejection FractionPerformance measures for pneumonia: are they valuable, and are process measures adequate?Section 7: Heart Failure in Patients With Left Ventricular Systolic DysfunctionComing Together to Achieve Quality Cardiovascular Care 1 March 2005Volume 142, Issue 5Page: 386-387KeywordsACE inhibitorsHealth careHealth care qualityHealth care quality assessmentHealth services researchHeart failureResearch quality assessment ePublished: 1 March 2005 Issue Published: 1 March 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...